Medicare does cover PSMA PET scans for prostate cancer, though the specific terms of that coverage have evolved as the technology has matured. The two FDA-approved PSMA-targeting agents, Gallium-68 PSMA-11 and piflufolastat F 18 (sold as Pylarify), both gained approval in 2020 and 2021 respectively, and Medicare reimbursement followed. The path to broad coverage was not instant, and how smoothly you access a scan today still depends on factors like your clinical situation, where you live, and whether your provider documents the order correctly.
How Coverage Developed
When PSMA PET scans first received FDA clearance, Medicare initially covered them under a framework called “coverage with evidence development,” which required patients to be enrolled in a registry so that real-world data could be collected alongside clinical use. That approach was common for newer imaging technologies where the evidence base was still growing. Medicare has historically set the pace for PET reimbursement in the United States, and its decisions tend to influence what private insurers will cover as well.
Over time, as clinical trial data accumulated showing the value of PSMA PET imaging, the Centers for Medicare and Medicaid Services (CMS) broadened access. Medicare not only provides reimbursement for PET imaging procedures for its beneficiaries but also sets an example that third-party insurers tend to follow, though challenges remain with reimbursement levels and the application of appropriate-use criteria for imaging procedures.1Springer Link / Europe PMC. Regulatory Agencies and PET/CT Imaging in the Clinic By 2024, CMS had moved toward broader national coverage that removed many of the earlier registry requirements, making it easier for patients and providers to access PSMA PET scans through standard Medicare billing channels.
Which Clinical Situations Qualify
Medicare coverage for PSMA PET scanning generally applies to two main clinical scenarios in prostate cancer care. The first is initial staging, where a patient with newly diagnosed prostate cancer needs to know whether the disease has spread beyond the prostate. The second is biochemical recurrence, where a patient’s PSA level begins rising after treatment like surgery or radiation, suggesting the cancer may have returned or spread, but conventional imaging has not pinpointed where.
For initial staging, the National Comprehensive Cancer Network recommends PSMA PET/CT or PSMA PET/MRI as one of several acceptable imaging options for patients with unfavorable intermediate-risk prostate cancer. The NCCN defines acceptable “soft-tissue imaging” as CT of the chest, abdomen, and pelvis, MRI of the abdomen and pelvis, or PSMA PET. This is framed as a soft recommendation where PSMA PET can be considered as an option without being stated as the preferred choice. The NCCN also considers PSMA PET a suitable alternative for bone imaging, though it only recommends bone imaging when regional or distant spread has been found on soft-tissue imaging.2BJU International. Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate‐risk prostate cancer For higher-risk disease, the guidelines are even more supportive of using PSMA PET upfront.
For biochemical recurrence, PSMA PET has become something of a default in many practices because it can detect recurrent disease at much lower PSA levels than older imaging methods. This is the scenario where the evidence for PSMA PET’s superiority is arguably strongest, and it is the clinical context where Medicare coverage has been most firmly established.
Why PSMA PET Gets Covered When Older Scans Existed
The clinical evidence supporting PSMA PET imaging over conventional alternatives is what drove Medicare to cover it in the first place. In patients with biochemically recurrent prostate cancer, one study found that PSMA PET/CT had a sensitivity of 100% compared with just over 58% for conventional imaging on a per-lesion basis, and overall patient-level accuracy of about 91% versus 62% for conventional methods.3PubMed Central. 18 F‐PSMA‐1007 PET/CT Demonstrates Higher Accuracy for Biochemically Recurrent Prostate Cancer Compared to Contemporary Conventional Imaging That kind of gap in diagnostic accuracy is hard for a coverage committee to ignore, particularly when catching recurrent disease early can change treatment decisions.
The picture is a bit more nuanced for detecting bone metastases specifically. A phase 2 trial comparing PSMA PET/CT to the combination of bone scan plus CT in patients progressing on androgen deprivation therapy found that both approaches had identical per-patient detection rates for bone lesions. However, PSMA PET/CT found more individual bone lesions than the conventional approach in about a quarter of patients, while bone scan plus CT found more in fewer than one in ten patients.4Scientific Reports. Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy The difference in lesion counts per patient did not reach statistical significance in that trial, but the overall trend favored PSMA PET. In practice, this means PSMA PET does not always dramatically outperform older scans for bone disease, but it rarely misses what the older scans catch, and it often finds additional disease.
The real strength of PSMA PET lies in its ability to detect disease in soft tissues and lymph nodes that conventional CT and bone scans routinely miss, especially at low PSA levels. This capability is what makes it particularly valuable in the biochemical recurrence setting, where PSA may be barely detectable but treatment decisions hinge on knowing whether the recurrence is local or distant.
What You Might Still Owe Out of Pocket
Even with Medicare coverage, a PSMA PET scan is not free. Under traditional Medicare (Part B), you are responsible for the standard 20% coinsurance after meeting your annual deductible. PSMA PET scans are not cheap procedures; the radiopharmaceutical agent alone can cost several thousand dollars, and the imaging facility charges on top of that. Your 20% share can realistically run into several hundred dollars or more depending on the facility and region.
If you have a Medicare Advantage plan, the specifics depend on your plan’s cost-sharing structure. Most Medicare Advantage plans cover the same services as traditional Medicare, but they may impose different copayment amounts, require prior authorization, or restrict you to in-network imaging centers. Prior authorization is a common friction point: your oncologist or urologist may need to submit documentation showing the scan meets appropriate-use criteria before the plan will approve it. This adds time to an already stressful process.
Medigap (Medicare Supplement) plans can cover part or all of the 20% coinsurance if you are on traditional Medicare. If you carry a Plan F or Plan G supplement, your out-of-pocket cost for the scan itself may be minimal or zero. Patients without supplemental coverage should ask the imaging facility for an estimate before scheduling.
The Cost-Effectiveness Debate
Whether PSMA PET scanning is worth its cost from a health-system perspective is a separate question from whether Medicare covers it, but it is a question that shapes future coverage decisions and has some surprising wrinkles. A modeling study of patients with biochemical recurrence found that using PSMA PET upfront was associated with higher quality-adjusted life years compared with the conventional strategy of CT plus bone scan, but also with substantially higher costs. The resulting cost-effectiveness ratio exceeded $150,000 per quality-adjusted life year gained, which is the threshold economists typically use to define good value in U.S. healthcare.5PubMed Central. Cost-Effectiveness and Evidence Gaps Surrounding PSMA-PET for Recurrent Prostate Cancer Evaluation In other words, PSMA PET improved outcomes but at a price that, on average, was higher than what is usually considered cost-effective.
There was an important caveat, though. In patients with lower PSA levels at the time of recurrence, the cost-effectiveness picture improved considerably, dropping to about $113,000 per quality-adjusted life year. This makes intuitive sense: PSMA PET’s biggest advantage is detecting disease that conventional scans miss, and that advantage is largest when PSA is low and conventional imaging is essentially blind. At higher PSA levels, conventional imaging catches more of what is there, and the added cost of PSMA PET buys less incremental information.5PubMed Central. Cost-Effectiveness and Evidence Gaps Surrounding PSMA-PET for Recurrent Prostate Cancer Evaluation
For initial diagnosis rather than recurrence, the economics look somewhat different. A separate analysis found that piflufolastat F 18 (the Pylarify agent) was more cost-effective than older PET tracers and standard-of-care imaging for initial prostate cancer diagnosis, with the highest net monetary benefit at a $150,000 willingness-to-pay threshold.6PubMed Central. Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States The difference in cost-effectiveness between initial staging and recurrence likely reflects the higher stakes and more treatment-altering impact of accurate staging at the point of first diagnosis.
Geographic Access Is Uneven
Having Medicare coverage on paper does not guarantee easy access to a PSMA PET scan in practice. The radiopharmaceuticals used in PSMA PET have very short half-lives, meaning they are produced in a cyclotron or generator and must be transported to an imaging facility for injection within hours. If a facility is far from the production site, the tracer may expire before it arrives, which creates a genuine logistical bottleneck for patients in rural or remote areas.7PubMed Central. Geographic variability in contemporary utilization of PET imaging for prostate cancer: a medicare claims cohort study
This infrastructure requirement contributes to measurable disparities in who actually gets PSMA PET imaging. A Medicare claims study documented significant geographic variability in PET utilization for prostate cancer across metropolitan, urban, and rural regions.7PubMed Central. Geographic variability in contemporary utilization of PET imaging for prostate cancer: a medicare claims cohort study If you live in or near a major medical center, you probably have straightforward access to PSMA PET. If you are in a rural area, you may need to travel to an urban imaging facility, potentially several hours away. Some patients arrange to combine the scan trip with a consultation at a cancer center, which can make the travel more worthwhile but adds complexity to scheduling.
The two approved PSMA agents have slightly different half-lives. Gallium-68 PSMA-11 has a half-life of about 68 minutes, which limits its distribution radius severely. Piflufolastat F 18 uses fluorine-18 with a roughly two-hour half-life, giving it a somewhat larger practical distribution range. Facilities that cannot obtain Gallium-68 in time may have better luck with the fluorine-18 agent, and this practical consideration sometimes determines which tracer is available at a given location rather than any clinical preference.
How to Improve Your Chances of Smooth Coverage
The most common reason for a PSMA PET claim to be denied or delayed is incomplete documentation from the ordering provider. Medicare and Medicare Advantage plans expect the referring physician to demonstrate that the scan meets clinical criteria. In practice, this means the order should clearly state your diagnosis, current PSA level, Gleason score or grade group, and the clinical question the scan is meant to answer, whether that is initial staging, biochemical recurrence workup, or assessment before a specific treatment like radiation therapy.
If you are on a Medicare Advantage plan, ask your doctor’s office whether prior authorization is required before the scan is scheduled. Getting authorization after the fact is far harder than getting it beforehand. If authorization is denied, your doctor can appeal, and appeals based on guideline-concordant indications have a reasonable success rate since the NCCN guidelines explicitly include PSMA PET as an appropriate option.
Ask the imaging facility whether they are Medicare-participating and whether they bill Medicare directly. Outpatient hospital-based imaging departments and freestanding imaging centers may bill differently under Medicare’s outpatient prospective payment system, and the facility fee component can vary. Freestanding centers sometimes have lower total charges, which reduces your coinsurance share, though availability of PSMA agents may be more limited outside hospital settings.
When a PSMA PET Scan May Not Be the Right Call
Not every prostate cancer patient benefits from PSMA PET imaging. For men with very low-risk or favorable intermediate-risk disease, where the probability of metastatic spread is minimal, the scan is unlikely to change management and guideline bodies do not recommend it. Ordering it in that context could lead to incidental findings that prompt unnecessary biopsies or anxiety without improving outcomes.
There is also a small but real false-positive rate. PSMA is expressed in some non-cancerous tissues, and benign conditions can occasionally light up on a PSMA PET scan. A suspicious finding on PSMA PET does not always mean cancer has spread; it may require additional workup to confirm. This is another reason guidelines recommend PSMA PET selectively, in clinical contexts where the pre-test probability of metastatic disease is high enough that a positive result is more likely to be a true positive.
About 5 to 10% of prostate cancers have low or absent PSMA expression, meaning the scan can miss them entirely. These PSMA-negative tumors tend to be certain aggressive variants. If your oncologist suspects a PSMA-low tumor based on pathology or clinical behavior, other imaging approaches may be more appropriate, and this is a conversation worth having before assuming PSMA PET is the best option for your specific case.
Private Insurance and PSMA PET
If you are not yet on Medicare, the coverage landscape for PSMA PET through private insurance is less uniform. Many large commercial insurers now cover PSMA PET for at least some prostate cancer indications, following Medicare’s lead. But the criteria for coverage vary by insurer, and some plans still require step therapy, meaning you must have a conventional scan first and only get PSMA PET if the conventional scan is inconclusive or negative despite a rising PSA.
Self-pay costs for a PSMA PET scan typically range from $3,000 to $6,000 or more, depending on the facility and tracer used. Some imaging centers offer cash-pay discounts, and a handful of clinical trials still provide PSMA PET scans at no cost to participants. If coverage is denied and you believe the scan is clinically appropriate, the peer-to-peer review process, where your doctor speaks directly with the insurer’s medical director, is often the most effective route to overturn the decision.
The broader trend is toward wider coverage as the evidence base grows and as oncology guidelines more firmly integrate PSMA PET into standard prostate cancer workups. Several years ago, getting any insurer to pay for a PSMA PET scan required navigating a thicket of exceptions and appeals. Today, for Medicare beneficiaries in particular, the process is substantially more straightforward, even if it is not yet frictionless.